英國(guó)一家公司正計(jì)劃進(jìn)行一項(xiàng)新技術(shù)的臨床試驗(yàn),，公司稱這一技術(shù)能將白細(xì)胞轉(zhuǎn)化為可用于治療白血病和多種其它疾病的干細(xì)胞,。
設(shè)在倫敦的TriStem 公司稱他們發(fā)明的這個(gè)方法將消除從胚胎和胎兒獲得干細(xì)胞的需要,。早期胚胎的應(yīng)用所涉及的倫理問題一直是阻礙干細(xì)胞應(yīng)用的一個(gè)主要障礙。
TriStem幾年前就聲稱他們能抽取任何人的半升血液,，從中提取出白細(xì)胞,，誘導(dǎo)它們回退到干細(xì)胞的狀態(tài)。現(xiàn)在這家公司最終提供的證據(jù)至少可以證明他們?cè)缦嚷暶髦械囊徊糠质钦鎸?shí)的,。
TriStem用這一技術(shù)將白細(xì)胞轉(zhuǎn)化為存在于骨髓中的干細(xì)胞,，然后導(dǎo)入到小鼠體內(nèi)，結(jié)果細(xì)胞分化為不同類型的血液細(xì)胞,。但一些著名的干細(xì)胞研究專家對(duì)公司的報(bào)道表示懷疑,，他們表示還需要看到更多的證據(jù)才能確信這一技術(shù)的有效性。
TriStem已被批準(zhǔn)用這個(gè)技術(shù)治療來自一個(gè)不知名國(guó)家的12名再生障礙性貧血(Aplastic Anemia)病人,。
“合作進(jìn)行此次臨床試驗(yàn)的當(dāng)?shù)卣块T要求公司就病人的國(guó)籍和身份保密,。”公司補(bǔ)充說。
TriStem的科學(xué)家計(jì)劃用衍生自組織匹配供體的干細(xì)胞進(jìn)行這次臨床試驗(yàn),。預(yù)計(jì)明年3月會(huì)產(chǎn)生結(jié)果,。“一周內(nèi)，我們應(yīng)該就能發(fā)現(xiàn)細(xì)胞是否轉(zhuǎn)化為干細(xì)胞,。”公司的合伙人Ilham Saleh Abuljadayel說,。
原文：
British firm plans human stem cell trial: report
A British company is planning human trials of a new technique which it says can transform white blood cells into stem cells that can be used to treat leukaemia and a range of other diseases.
London-based TriStem says the method it has developed eliminates the need for embryos and foetuses, rich sources of the stem cells that can develop into any cell type.
The use of early embryos has been a major stumbling block in the use of stem cells.
"TriStem has been claiming for years that it can take a half litre of anyone's blood, extract the white blood cells and make them revert to a stem cell-like state," New Scientist magazine reported.
"The company has now finally provided proof that at least some of its claims might be true."
The company used the technique to turn white blood cells into stem cells found in bone marrow, and injected them into mice to produce different types of blood cells.
It is due to report its findings in a peer-review journal in March.
But some leading stem-cell researchers are sceptical about the company's claims and say more proof is needed.
TriStem has been granted permission to use the technology to treat a dozen patients with a bone marrow disorder called aplastic anaemia in an unnamed country, according to the magazine.
"Senior government research collaborators in the country hosting the trial have asked for the location to be kept secret for now," it said.
Scientists at TriStem plan to use stem cells derived from tissue-matched donors for the trial. The results are due by March.
"Within a week, we should find if the cells have taken," said Dr Ilham Saleh Abuljadayel, a co-founder of the company.
